Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
8000 participants
OBSERVATIONAL
2021-11-01
2023-03-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Using state-of-the-art statistics and machine learning (ML)-based analyses, This project aims to improve prediction and prevention of heart failure (HF) in AMI patients and understand progression or regression of HF in AHF patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute myocardial infarction (AMI) and acute heart failure (AHF)
All patients identified with the respective International Statistical Classification of Diseases and Related Health Problems (ICD) 10th revision codes for AMI and/or the phenotype of "AHF" will undergo detailed medical review to verify patients' diagnosis of AMI and/or AHF according to current European Society of Cardiology (ESC) guidelines that are reflected in the subsequent inclusion criteria.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Hospitalized with a primary diagnosis of AMI
a) ST-segment elevation Myocardial Infarction (STEMI) and Non-STEMI (NSTEMI) have to fulfil the 4th universal definition of myocardial infarction.
* Acute myocardial injury with dynamic cardiac troponin (cTn) changes (at least one value above 99th per-centile URL) AND
* At least ONE of the following:
* Symptoms of myocardial ischemia
* New ischemic ECG changes or new pathological Q waves
* Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality consistent with ischemic etiology
* Intracoronary thrombus on angiography (or autopsy) AND/OR
3. Hospitalization with a primary diagnosis of AHF based on the following criteria:
1. Symptoms: progressive dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, AND/OR progressive peripheral oedema, weight gain.
AND at least TWO of the following:
2. Signs: basal pulmonary rales AND/OR peripheral oedema, jugular vein dilatation OR
3. N-terminal prohormone of brain natriuretic peptide (NT-proBNP) within 24 hours \>450 pg/ml if age \<50 years, \>900 pg/ml if age 50-75 years, \>1800 pg/ml if age \>75 years) OR BNP \>400 pg/ml. Cut-offs need to be reduced by 50% in case of severe obesity (BMI \>35) OR
4. Treatment of AHF within 24 h using the following drugs i) increased diuretics. iv furosemide or increased po furosemide or torasemide ii) inotropes (dobutamine, dopamine, levosimendan, milrinone) iii) i.v. or s.l. vasodilators (nitroglycerine, isosorbide dinitrate) iv) vasopressors (norepinephrine) OR e) Echocardiographic features (within 72 hours) -- automated TTE downloads left ventricular ejection fraction (LVEF) \<40% or estimated pulmonary artery systolic pressure (PASP) \>40 mmHg or increased estimated right atrium pressure (RA) pressure above 10 mmHg (VCI size / resp. motion)
1. Female or male patients, age \> 18 years
2. ECG and TTE recording performed within 5 days of each other
3. TTE is labelled as "normal".
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
University Hospital, Basel, Switzerland
OTHER
University of Bern
OTHER
ETH Zurich
OTHER
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian M Matter, MD
Role: PRINCIPAL_INVESTIGATOR
University of Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Basel
Basel, , Switzerland
University Hospital, Bern
Bern, , Switzerland
University Hospital, Geneva
Geneva, , Switzerland
University Hospital, Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHFN Swissheart
Identifier Type: -
Identifier Source: org_study_id